Novel biotin-linked amphiphilic calix[4]arene-based supramolecular micelles as doxorubicin carriers for boosted anticancer activity

The lack of targeting, severe toxicity on normal tissues have become an intractable limitation of doxorubicin (DOX)-based chemotherapy. A biotin-modified calix[4]arene based therapeutic agent BPCA4 has been designed for the delivery of DOX to alleviate the adverse side effects.